Get up to speed on herpes simplex virus (HSV-1/HSV-2) epidemiology, novel antibodies, vaccine development, and cure ...
Background. Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herpes simplex virus type 2 (HSV-2) in HSV-2–serodiscordant heterosexual couples by 48%. Whether ...
HealthDay News — A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general ...
HSV-1 usually causes oral herpes, while HSV-2 primarily affects the genitals. You may not know you have herpes because it ...
The rise of sexually transmitted infections (STIs) continues to pose threats. The prevalence of one uncurable STI in particular – genital herpes simplex virus (HSV) type 1 and 2 – is at a global high, ...
This is a preview. Log in through your library . Abstract Background and Objectives: The genital herpes epidemic continues, in part, because patients with subclinical or atypical presentations cannot ...
Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...
– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback